• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Gene Panel Market size worth $ 8.22 Million, Globally, by 2028 at 21.36% CAGR: Verified Market Research®

    10/13/21 11:15:00 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care
    Get the next $GNMK alert in real time by email

    Jersey City, New Jersey, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, "Gene Panel Market" By Technique (Amplicon-Based Approach, Hybridization-Based Approach), By Design (Predesigned Gene Panels, Customized Gene Panels), By Application (Pharmacogenetics, Diagnosis of Congenital Disorders, Cancer Risk Assessment, Others), and By Geography. According to Verified Market Research, the Global Gene Panel Market size was valued at USD 1.70 Billion in 2020 and is projected to reach USD 8.22 Billion by 2028, growing at a CAGR of 21.36% from 2021 to 2028.

    Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=29123

    Browse in-depth TOC on "Gene Panel Market"

    202 - Pages

    126 – Tables

    37 – Figures

    Global Gene Panel Market Overview

    The gene panels are used in diagnostics and treatments such as; Cancer Risk Assessment, Syndrome-Specific Diagnostics, Disease Penetration, and many other applications. Based on the data published by the World Health organization, in 2020, the chronic disease contribution is expected to rise to 73% of all deaths and 60% of the global burden of disease. Moreover, 79% of the deaths attributed to these diseases occur in developing countries. Four of the most prominent chronic diseases are cardiovascular diseases (CVD), cancer, chronic obstructive pulmonary disease, and diabetes. This will ultimately upsurge the demand for gene panels over the forecasted period. A multi-gene panel test provides better diagnostic yield compared with a limited BRCA1/2 genetic test for patients at risk for hereditary breast cancer. This single reliable test provides more information for women suspected to have hereditary cancer predisposition, particularly for breast and ovarian cancers. Besides this, in a retrospective comparison of multiple genetic tests, there was no difference between the multi-gene panel test and the limited BRCA1/2 test in the detection of potentially harmful BRCA mutations.

    Genetic data is the most personal data any individual may have. Also, it is an ultimate unique identifier of all living things. Besides this, the information breaches regarding the same can't be retrieved since it is not like other websites and banking passwords that can be changed over time. The gene data for each of the living things across the world is unique and cannot be changed throughout a lifetime. This might restrict the usage of gene testing across the healthcare and research & development sector. Since the data is so valuable, there may be an incentive for hackers to target genetic databases in order to acquire data that can be used in financial or identity fraud.

    Key Developments in Gene Panel Market

    • Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic. With this partnership, Illumina will expand the TruSight Oncology offerings into hematologic malignancies.
    • F. Hoffmann-La Roche AG has commenced a cash tender offer for all of the outstanding shares of common stock of Gen Mark Diagnostics, Inc. (NASDAQ:GNMK) at a price of $24.05 per share.

    The major players in the market are BGI, Genewiz, Inc., Thermo Fisher Scientific Inc., Novogene Corporation, Qiagen, Integrated DNA Technologies, and the rest Others.

    Verified Market Research has segmented the Global Gene Panel Market On the basis of Technique, Design, Application, and Geography.

    • Gene Panel Market, By Technique
      • Amplicon-Based Approach
      • Hybridization-Based Approach
    • Gene Panel Market, By Design
      • Predesigned Gene Panels
      • Customized Gene Panels
    • Gene Panel Market, By Application
      • Pharmacogenetics
      • Diagnosis of Congenital Disorders
      • Cancer Risk Assessment
      • Others
    • Gene Panel Market by Geography
      • North America
        • U.S
        • Canada
        • Mexico
      • Europe
        • Germany
        • France
        • U.K
        • Rest of Europe
      • Asia Pacific
        • China
        • Japan
        • India
        • Rest of Asia Pacific
      • ROW
        • Middle East & Africa
        • Latin America

    Browse Related Reports:

    Transplant Diagnostics Market By Technology (Molecular array, Non-molecular array), By Products and Services (Instruments, Reagents, and consumables, Software and services), By End-User (Hospitals and transplants centers, Commercial service providers), By Geography, Forecast, 2021-2028

    Hospital Asset Management Market By Product (Radiofrequency Identification (RFID) Devices and Real-time location systems (RTLS)), By Application (Hospital Asset Management and Pharmaceutical Asset Management), By End-User (Hospitals and Clinics, Pharmaceutical Companies), By Geography, Forecast, 2021-2028

    Pharmaceutical Manufacturing Software Market By Product (On-premises and Cloud-Based), By Application (Large Enterprises and SMEs), By Geography, Forecast, 2021-2028

    Medical Display Market By Display Color(Monochrome Displays, and Color Displays), By Panel Size(Under-22.9-Inch Panels, 23.0–26.9-Inch Panels, 27.0–41.9-Inch Panels), By Technology(LED-Backlit LCD, OLED, and CCFL-Backlit LCD), By Application(Diagnostic Applications, Surgical/Interventional Applications, Dentistry), By Geography, Forecast, 2021-2028

    Top 10 next generation sequencing companies changing lives with genome research

    Visualize Gene Panel Market using Verified Market Intelligence:-:

    Verified Market Intelligence is our BI Enabled Platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue impacting decisions for a brilliant future.

    VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

    About Us

    Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

    Our 250 Analysts and SME's offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

    We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defense, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & Construction, Agriculture industry and Medical Devices from over 100 countries.



    Mr. Edwyne Fernandes
    Verified Market Research®
    US: +1 (650)-781-4080
    UK: +44 (753)-715-0008
    APAC: +61 (488)-85-9400
    US Toll Free: +1 (800)-782-1768
    Email: [email protected]
    Web: https://www.verifiedmarketresearch.com/
    BI Enabled Platform: https://www.verifiedmarketresearch.com/vmintelligence/
    Follow Us: LinkedIn | Twitter

    Primary Logo

    Get the next $GNMK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNMK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNMK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Giles Lisa M. decreased direct ownership by 100% to 0 units to satisfy tax liability

    4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

    4/22/21 1:55:57 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Fox James decreased direct ownership by 100% to 0 units to cover taxes

    4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

    4/22/21 1:55:12 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Kagnoff Michael decreased direct ownership by 100% to 0 units to satisfy tax liability

    4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

    4/22/21 1:55:32 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    SEC Filings

    View All

    SEC Form 15-12B filed by GenMark Diagnostics, Inc.

    15-12B - GenMark Diagnostics, Inc. (0001487371) (Filer)

    5/3/21 4:02:03 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by GenMark Diagnostics, Inc.

    EFFECT - GenMark Diagnostics, Inc. (0001487371) (Filer)

    4/28/21 12:15:09 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by GenMark Diagnostics, Inc.

    S-8 POS - GenMark Diagnostics, Inc. (0001487371) (Filer)

    4/22/21 4:22:52 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gene Panel Market size worth $ 8.22 Million, Globally, by 2028 at 21.36% CAGR: Verified Market Research®

    Jersey City, New Jersey, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, "Gene Panel Market" By Technique (Amplicon-Based Approach, Hybridization-Based Approach), By Design (Predesigned Gene Panels, Customized Gene Panels), By Application (Pharmacogenetics, Diagnosis of Congenital Disorders, Cancer Risk Assessment, Others), and By Geography. According to Verified Market Research, the Global Gene Panel Market size was valued at USD 1.70 Billion in 2020 and is projected to reach USD 8.22 Billion by 2028, growing at a CAGR of 21.36% from 2021 to 2028. Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=29123 Browse in-de

    10/13/21 11:15:00 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash

    Basel, 25 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of GenMark Diagnostics, Inc. (NASDAQ: GNMK) at a price of $24.05 per share. The tender offer is being made pursuant to the previously announced merger agreement dated as of March 12, 2021 among Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, Geronimo Acquisition Corp., a wholly owned subsidiary of Roche Holdings, Inc., and GenMark. The tender offer period will expire at 12:00 midnight, Eastern Time, at the end of the day on Wednesday, April 21, 2021, unless the offer is extended. Roche

    3/25/21 12:40:00 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample

    Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sampleGenMark’s ePlex platform delivers rapid and actionable results so clinicians can determine the cause of infection and the most effective treatment, potentially saving lives and alleviating the healthcare burden. The addition of GenMark’s proprietary multiplex technology complements Roche’s diagnostic offering, addressing a broad range of infectious disease testing needs, including respiratory and bloodstream infections              Basel, 15 March 2021 - Roc

    3/15/21 2:00:00 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GenMark Diagnostics downgraded by BTIG

    BTIG downgraded GenMark Diagnostics from Buy to Neutral

    3/17/21 7:31:42 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    GenMark Diagnostics downgraded by Cowen & Co. with a new price target

    Cowen & Co. downgraded GenMark Diagnostics from Outperform to Market Perform and set a new price target of $24.05 from $23.00 previously

    3/17/21 6:46:59 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    GenMark Diagnostics downgraded by Canaccord Genuity

    Canaccord Genuity downgraded GenMark Diagnostics from Buy to Hold

    3/16/21 10:34:41 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    $GNMK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by GenMark Diagnostics, Inc. (Amendment)

    SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)

    5/10/21 11:58:21 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by GenMark Diagnostics, Inc. (Amendment)

    SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)

    4/12/21 1:05:52 PM ET
    $GNMK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by GenMark Diagnostics, Inc.

    SC 13D - GenMark Diagnostics, Inc. (0001487371) (Subject)

    3/26/21 9:07:58 AM ET
    $GNMK
    Medical/Dental Instruments
    Health Care